Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 3 clinical study of Vezocolmitide

Next Previous
Trial Profile

Phase 3 clinical study of Vezocolmitide

Status: Planning
Phase of Trial: Phase III

Latest Information Update: 02 Sep 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vezocolmitide (Primary)
  • Indications Dry eyes
  • Focus Registrational; Therapeutic Use
  • Sponsors Stuart Therapeutics

Most Recent Events

  • 26 Aug 2026 According to Stuart Therapeutics media release, ST-100 is expected to begin Phase 3b clinical trials in the first quarter of 2027.
  • 30 Jun 2025 New trial record
  • 24 Jun 2025 According to Stuart Therapeutics media release, company is finalizing a plan for an additional clinical trial using the results from the present Phase III trial to help guide the trial design. The Company also intends to engage with the U.S. Food and Drug Administration (FDA) to confirm the design of this additional trial, and the regulatory path to approval of ST-100.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top